IGF2BP2 drives AML progression by m6A-dependently controlling glutamine metabolic regulators (MYC/GPT2/SLC1A5), sustaining leukemic stem cell self-renewal (210). The gene discussed is IGF2BP2; the disease is acute myeloid leukemia.